Figure 6 | Scientific Reports

Figure 6

From: Latent-period stool proteomic assay of multiple sclerosis model indicates protective capacity of host-expressed protease inhibitors

Figure 6

Vancomycin alters stool proteome and reduces protease inhibitor abundance. (A) Timeline of vancomycin treatment and stool collection schedule. (B) PCA of Vancomycin and untreated groups over the time course. Graph was generated from the subset of proteins (N = 177) that differentiated each day and group using statistically significant (two-way ANOVA, Bonferroni correction p < 0.05) (C). Two-way ANOVA of intestinal alkaline phosphatase levels over the time course (Bonferroni’s correction, **p < 0.01; F (4, 56) = 22.35). (D) Mean clinical score over course of study. The non-antibiotic treated group exhibited significantly (two-way ANOVA, Bonferroni correction p < 0.05) increased mean scores compared to their vancomycin-treated counterpart at every point past DPI 9. (E) Two-way ANOVA comparison between VT and untreated mice of Reg3-family AMP abundance over time (two-way ANOVA, Bonferroni correction p < 0.05). (F) Time course comparison of selected protease inhibitor abundance found in vancomycin-treated and non-treated mice stool (two-way ANOVA, Bonferroni correction p < 0.05; See Supplementary Table 8 for complete statistics).

Back to article page